Latest Regulatory Approvals News

BCAL Diagnostics has launched its Avantect blood tests for pancreatic and ovarian cancer with encouraging early uptake and is advancing its BREASTESTplus breast cancer test towards broader clinical use.

Santana Minerals has secured a clear statutory timeline for the Bendigo-Ophir Gold Project fast-track approval, with a decision expected by late October 2026. The appointment of a seven-member Expert Panel marks a significant step in the project's regulatory journey.

Lake Resources has clarified its latest cash flow report, highlighting $666k spent on environmental and power solution explorations while advancing key regulatory approvals for its Kachi lithium project. The company maintains a robust liquidity position and benefits from new technology partnerships aimed at reducing costs.

Australian Critical Minerals Ltd has updated its Flint Gold-Silver Project presentation, confirming drill readiness with permits and funding secured for an initial diamond drilling program in Peru’s prolific epithermal belt.

Micro-X has initiated installation of its first human pilot site for a portable Head CT scanner at Royal Melbourne Hospital, marking a pivotal step towards revolutionising stroke diagnosis with carbon nanotube technology.

TG Metals Limited has reported strong new drilling results from its Van Uden Gold Project, confirming increased gold continuity and extensions to its existing resource. Diamond core drilling has commenced, aiming to further expand the mineral resource estimate.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

PYC Therapeutics has successfully closed a $537 million institutional placement and entitlement offer, positioning the company to raise at least $600 million to advance its RNA-based therapies targeting genetic diseases.

Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.

Bellavista Resources has successfully raised A$35 million through a two-tranche placement to fund its strategic acquisition and exploration plans in Canada and Australia.

Dalaroo Metals has mobilised its geological team to progress the Bongouanoa Gold Project in Côte d’Ivoire toward drill-ready status, leveraging promising historical gold intercepts and systematic fieldwork. The company is preparing for aircore and diamond drilling programs pending regulatory approvals.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.